Abstract
Summary
The global market for Oligonucleotide API was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Oligonucleotide API was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oligonucleotide API was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Oligonucleotide API was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Oligonucleotide API include Jazz Pharmaceuticals, Sarepta Therapeutics, Biogen, Dynavax Technologies, Akcea Therapeutics, Alnylam Pharmaceuticals, Nitto Denko (Avecia), Ajinomoto (GeneDesign) and RiboBio, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide API, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Oligonucleotide API by region & country, by Type, and by Application.
The Oligonucleotide API market size, estimations, and forecasts are provided in terms of sales volume (Ton) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide API.
Market Segmentation
By Company
Jazz Pharmaceuticals
Sarepta Therapeutics
Biogen
Dynavax Technologies
Akcea Therapeutics
Alnylam Pharmaceuticals
Nitto Denko (Avecia)
Ajinomoto (GeneDesign)
RiboBio
Segment by Type:
Antisense Oligonucleotides API
Small Interfering RNA (siRNA) API
MiRNA API
CpG Oligonucleotides API
Others
Segment by Application
Contract Manufacturing Organizations (CMOs)
Pharmaceutical Companies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Oligonucleotide API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Oligonucleotide API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Oligonucleotide API in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
North American market for Oligonucleotide API was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oligonucleotide API was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Oligonucleotide API was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Oligonucleotide API include Jazz Pharmaceuticals, Sarepta Therapeutics, Biogen, Dynavax Technologies, Akcea Therapeutics, Alnylam Pharmaceuticals, Nitto Denko (Avecia), Ajinomoto (GeneDesign) and RiboBio, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide API, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Oligonucleotide API by region & country, by Type, and by Application.
The Oligonucleotide API market size, estimations, and forecasts are provided in terms of sales volume (Ton) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide API.
Market Segmentation
By Company
Jazz Pharmaceuticals
Sarepta Therapeutics
Biogen
Dynavax Technologies
Akcea Therapeutics
Alnylam Pharmaceuticals
Nitto Denko (Avecia)
Ajinomoto (GeneDesign)
RiboBio
Segment by Type:
Antisense Oligonucleotides API
Small Interfering RNA (siRNA) API
MiRNA API
CpG Oligonucleotides API
Others
Segment by Application
Contract Manufacturing Organizations (CMOs)
Pharmaceutical Companies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Oligonucleotide API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Oligonucleotide API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Oligonucleotide API in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Oligonucleotide API Product Introduction
1.2 Global Oligonucleotide API Market Size Forecast
1.2.1 Global Oligonucleotide API Sales Value (2019-2030)
1.2.2 Global Oligonucleotide API Sales Volume (2019-2030)
1.2.3 Global Oligonucleotide API Sales Price (2019-2030)
1.3 Oligonucleotide API Market Trends & Drivers
1.3.1 Oligonucleotide API Industry Trends
1.3.2 Oligonucleotide API Market Drivers & Opportunity
1.3.3 Oligonucleotide API Market Challenges
1.3.4 Oligonucleotide API Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Oligonucleotide API Players Revenue Ranking (2023)
2.2 Global Oligonucleotide API Revenue by Company (2019-2024)
2.3 Global Oligonucleotide API Players Sales Volume Ranking (2023)
2.4 Global Oligonucleotide API Sales Volume by Company Players (2019-2024)
2.5 Global Oligonucleotide API Average Price by Company (2019-2024)
2.6 Key Manufacturers Oligonucleotide API Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Oligonucleotide API Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Oligonucleotide API
2.9 Oligonucleotide API Market Competitive Analysis
2.9.1 Oligonucleotide API Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Oligonucleotide API Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide API as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Antisense Oligonucleotides API
3.1.2 Small Interfering RNA (siRNA) API
3.1.3 MiRNA API
3.1.4 CpG Oligonucleotides API
3.1.5 Others
3.2 Global Oligonucleotide API Sales Value by Type
3.2.1 Global Oligonucleotide API Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Oligonucleotide API Sales Value, by Type (2019-2030)
3.2.3 Global Oligonucleotide API Sales Value, by Type (%) (2019-2030)
3.3 Global Oligonucleotide API Sales Volume by Type
3.3.1 Global Oligonucleotide API Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Oligonucleotide API Sales Volume, by Type (2019-2030)
3.3.3 Global Oligonucleotide API Sales Volume, by Type (%) (2019-2030)
3.4 Global Oligonucleotide API Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Contract Manufacturing Organizations (CMOs)
4.1.2 Pharmaceutical Companies
4.2 Global Oligonucleotide API Sales Value by Application
4.2.1 Global Oligonucleotide API Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Oligonucleotide API Sales Value, by Application (2019-2030)
4.2.3 Global Oligonucleotide API Sales Value, by Application (%) (2019-2030)
4.3 Global Oligonucleotide API Sales Volume by Application
4.3.1 Global Oligonucleotide API Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Oligonucleotide API Sales Volume, by Application (2019-2030)
4.3.3 Global Oligonucleotide API Sales Volume, by Application (%) (2019-2030)
4.4 Global Oligonucleotide API Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Oligonucleotide API Sales Value by Region
5.1.1 Global Oligonucleotide API Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Oligonucleotide API Sales Value by Region (2019-2024)
5.1.3 Global Oligonucleotide API Sales Value by Region (2025-2030)
5.1.4 Global Oligonucleotide API Sales Value by Region (%), (2019-2030)
5.2 Global Oligonucleotide API Sales Volume by Region
5.2.1 Global Oligonucleotide API Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Oligonucleotide API Sales Volume by Region (2019-2024)
5.2.3 Global Oligonucleotide API Sales Volume by Region (2025-2030)
5.2.4 Global Oligonucleotide API Sales Volume by Region (%), (2019-2030)
5.3 Global Oligonucleotide API Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Oligonucleotide API Sales Value, 2019-2030
5.4.2 North America Oligonucleotide API Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Oligonucleotide API Sales Value, 2019-2030
5.5.2 Europe Oligonucleotide API Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Oligonucleotide API Sales Value, 2019-2030
5.6.2 Asia Pacific Oligonucleotide API Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Oligonucleotide API Sales Value, 2019-2030
5.7.2 South America Oligonucleotide API Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Oligonucleotide API Sales Value, 2019-2030
5.8.2 Middle East & Africa Oligonucleotide API Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Oligonucleotide API Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Oligonucleotide API Sales Value
6.2.1 Key Countries/Regions Oligonucleotide API Sales Value, 2019-2030
6.2.2 Key Countries/Regions Oligonucleotide API Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Oligonucleotide API Sales Value, 2019-2030
6.3.2 United States Oligonucleotide API Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Oligonucleotide API Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Oligonucleotide API Sales Value, 2019-2030
6.4.2 Europe Oligonucleotide API Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Oligonucleotide API Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Oligonucleotide API Sales Value, 2019-2030
6.5.2 China Oligonucleotide API Sales Value by Type (%), 2023 VS 2030
6.5.3 China Oligonucleotide API Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Oligonucleotide API Sales Value, 2019-2030
6.6.2 Japan Oligonucleotide API Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Oligonucleotide API Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Oligonucleotide API Sales Value, 2019-2030
6.7.2 South Korea Oligonucleotide API Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Oligonucleotide API Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Oligonucleotide API Sales Value, 2019-2030
6.8.2 Southeast Asia Oligonucleotide API Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Oligonucleotide API Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Oligonucleotide API Sales Value, 2019-2030
6.9.2 India Oligonucleotide API Sales Value by Type (%), 2023 VS 2030
6.9.3 India Oligonucleotide API Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Jazz Pharmaceuticals
7.1.1 Jazz Pharmaceuticals Company Information
7.1.2 Jazz Pharmaceuticals Introduction and Business Overview
7.1.3 Jazz Pharmaceuticals Oligonucleotide API Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Jazz Pharmaceuticals Oligonucleotide API Product Offerings
7.1.5 Jazz Pharmaceuticals Recent Development
7.2 Sarepta Therapeutics
7.2.1 Sarepta Therapeutics Company Information
7.2.2 Sarepta Therapeutics Introduction and Business Overview
7.2.3 Sarepta Therapeutics Oligonucleotide API Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Sarepta Therapeutics Oligonucleotide API Product Offerings
7.2.5 Sarepta Therapeutics Recent Development
7.3 Biogen
7.3.1 Biogen Company Information
7.3.2 Biogen Introduction and Business Overview
7.3.3 Biogen Oligonucleotide API Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Biogen Oligonucleotide API Product Offerings
7.3.5 Biogen Recent Development
7.4 Dynavax Technologies
7.4.1 Dynavax Technologies Company Information
7.4.2 Dynavax Technologies Introduction and Business Overview
7.4.3 Dynavax Technologies Oligonucleotide API Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Dynavax Technologies Oligonucleotide API Product Offerings
7.4.5 Dynavax Technologies Recent Development
7.5 Akcea Therapeutics
7.5.1 Akcea Therapeutics Company Information
7.5.2 Akcea Therapeutics Introduction and Business Overview
7.5.3 Akcea Therapeutics Oligonucleotide API Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Akcea Therapeutics Oligonucleotide API Product Offerings
7.5.5 Akcea Therapeutics Recent Development
7.6 Alnylam Pharmaceuticals
7.6.1 Alnylam Pharmaceuticals Company Information
7.6.2 Alnylam Pharmaceuticals Introduction and Business Overview
7.6.3 Alnylam Pharmaceuticals Oligonucleotide API Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Alnylam Pharmaceuticals Oligonucleotide API Product Offerings
7.6.5 Alnylam Pharmaceuticals Recent Development
7.7 Nitto Denko (Avecia)
7.7.1 Nitto Denko (Avecia) Company Information
7.7.2 Nitto Denko (Avecia) Introduction and Business Overview
7.7.3 Nitto Denko (Avecia) Oligonucleotide API Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Nitto Denko (Avecia) Oligonucleotide API Product Offerings
7.7.5 Nitto Denko (Avecia) Recent Development
7.8 Ajinomoto (GeneDesign)
7.8.1 Ajinomoto (GeneDesign) Company Information
7.8.2 Ajinomoto (GeneDesign) Introduction and Business Overview
7.8.3 Ajinomoto (GeneDesign) Oligonucleotide API Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Ajinomoto (GeneDesign) Oligonucleotide API Product Offerings
7.8.5 Ajinomoto (GeneDesign) Recent Development
7.9 RiboBio
7.9.1 RiboBio Company Information
7.9.2 RiboBio Introduction and Business Overview
7.9.3 RiboBio Oligonucleotide API Sales, Revenue and Gross Margin (2019-2024)
7.9.4 RiboBio Oligonucleotide API Product Offerings
7.9.5 RiboBio Recent Development
8 Industry Chain Analysis
8.1 Oligonucleotide API Industrial Chain
8.2 Oligonucleotide API Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Oligonucleotide API Sales Model
8.5.2 Sales Channel
8.5.3 Oligonucleotide API Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer